Phase 1b clinical study of MB097 in combination with anti-PD1 in melanoma patients
Latest Information Update: 17 Apr 2023
At a glance
- Drugs MB 097 (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Microbiotica
- 12 Apr 2023 According to a Microbiotica media release, the company has entered into a clinical trial collaboration with MSD for this study.
- 30 Jun 2021 New trial record
- 23 Jun 2021 According to a Microbiotica media release, the company expect to initiate this trial in 2022.